

The meeting was called to order by Dr. James Vaughn at 9:05AM and adjourned at 9:31AM. A quorum (n=5) was present for the entirety of the meeting. Yarimar Torres Rosado was the assigned note-taker.

In accordance with institutional policy and NIH Guidelines, this IBC meeting was not open to the public to protect proprietary information and ensure confidentiality of sensitive research data.

Per the NIH Guidelines, only information related to recombinant or synthetic nucleic acid research is required to be publicly disclosed in the IBC minutes. Discussions involving research that falls outside the scope of the NIH Guidelines, internal updates, and sensitive or administrative matters may be redacted.

Members Present:

Name	Role	Affiliation
James Vaughn	Chair	UNE Faculty
Bob Kennedy	Ex-officio	UNE Director of Research Integrity
Ronnie Souza	Ex-officio	UNE Biological Safety Officer
Igor Prudovsky	Scientist; Unaffiliated member	MaineHealth Institute for Research
George Allen	Vice Chair	UNE Faculty
Derek Molliver	Scientist	UNE Faculty

Members Absent:

Name	Role	Affiliation
Richard Niles	Scientist; Unaffiliated member	Retired, no current institutional affiliation
Jamie Vaughn	Ex-Officio	UNE Director of Animal Care
Diana Goode	Scientist	UNE Faculty

Guests Present:

Name	Title	Affiliation
Elizabeth Day	EH&S Staff	UNE staff
Josh Mangin	Research Compliance Training Manager	UNE Staff
Yarimar Torres Rosado	IBC Compliance Coordinator	UNE Staff

Discussion Items:

1. Review of Previous Meeting Minutes

Date of Previous Meeting:	September 24 th , 2025
Motion:	N/A

The September meeting minutes were not provided at this meeting. They will be reviewed during the November meeting.

2. Full Committee Review

a. Submission #1

Project Overview:		
Submission Type:	Amendment	
IBC Protocol #:	090623-004	
Protocol Title:	Tuberous Sclerosis Complex: Mechanisms of Disease Pathogenesis	
Principal Investigator:	Harry Filippakis	
UNE Campus:	Biddeford	
Category of Research:	R/s DNA; Human derived cell lines; transgenic animals	
NIH Guideline Section:	III-A through III-F	
Risk Group:	2	
Proposed Biosafety Level:	BSL-2	
Proposed Animal Biosafety Level:	ABSL-2	
IBC Member Conflict of Interest:	None	
IBC Discussion Summary:		
General Review Items	Verified	Remarks
PI has the appropriate expertise and training in biosafety	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	11+ years of experience with synthetic/recombinant materials. Ph.D. in virology.
Laboratory staff have the appropriate expertise and training in biosafety	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A	Laboratory staff has relevant and appropriate CITI and hands on training.
Facilities are appropriate for the proposed research	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Facilities and space proposed appropriate for work.
Procedures and practices are appropriate for the proposed research	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Procedures and practices follow best guidelines for proposed work.
Containment conditions are appropriate	<input type="checkbox"/> BSL-1 <input checked="" type="checkbox"/> BSL-2	Containment conditions appropriate for BSL-2 work.
r/sNA Review Items	Remarks	
Agent characteristics (e.g., virulence, pathogenicity, environmental stability)	<p>The committee noted that this protocol was originally approved prior to the creation of the IBC Supplemental Form for Recombinant/Synthetic Nucleic Acid Research.</p> <p>The current amendment under review involves the addition of two new human-derived cell lines and did not include any changes to the previously approved recombinant or synthetic DNA work.</p> <p>As such, discussion of recombinant/synthetic DNA activities was not required, since it had already been reviewed and approved under the original submission.</p> <p>The committee reaffirmed that all new protocols involving recombinant or synthetic nucleic acid work must include the</p>	
Type of manipulations planned		
Source(s) of the nucleic sequences (e.g., species)		
Nature of the nucleic acid sequences (e.g., structural gene, oncogene)		
Host(s) and vector(s) to be used		
Whether an attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced		

